Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Opthea Ltd Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 6-K Quarterly results
09/28/2023 6-K Quarterly results
08/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Investor Presentation, dated 24 August 2023",
"Opthea announces Placement and fully underwritten Entitlement Offer to raise A$80.0 million Melbourne, Australia; 24 August 2023 - Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that the Company is seeking to raise A$80.0 million via a A$10.0 million private placement and a $70.0 million Accelerated Non-Renounceable Entitlement Offer . The proceeds from the Placement and Entitlement Offer will be used to continue advancing the clinical development of OPT-302 for the treatment of wet Age-related Macular Degeneration , including to progress the Company's Phase 3 clinical trials and for general corporate purposes. Dr Megan Baldwin, Chief Executive Officer and Managing Director o...",
"Australian Transaction Specific Prospectus, as filed with the Australian Stock Exchange on August 24, 2023"
08/01/2023 6-K Quarterly results
07/26/2023 6-K Quarterly results
07/24/2023 6-K Quarterly results
07/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting • Podium presentation on the pharmacokinetics and safety of OPT-302 in retinal vascular diseases • Participation in “Live From ASRS” virtual KOL discussion on market trends and new treatments in wet AMD hosted by Oppenheimer & Co. Melbourne, Australia; July 13, 2023 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that OPT-302, the Company’s first-in-class VEGF-C/D “trap” inhibitor will be highlighted during the upcoming American Society of Retina Specialists 2023 Annual Meeting in Seattle, Washington. The ASRS is the largest organization of retina spe..."
07/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor Melbourne, Australia; July 10, 2023 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today the resignation of Dr. Joel Naor, Chief Medical Officer , effective July 15th, 2023. Dr. Naor is stepping down to pursue new opportunities and will be replaced by Dr. Kenneth Sall, MD who has been appointed as Opthea's Senior Medical Advisor. Dr. Sall will assume responsibility for safety oversight of the Opthea’s Phase 3 clinical trials investigating OPT-302, a novel VEGF-C/D ‘trap’ inhibitor, for the treatment of wet age-related macular degeneration . Dr. Sall is an ophthalmology specialist ..."
06/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASX, Nasdaq and Media Release June 8, 2023 Opthea Appoints Anshul Thakral as Non-Executive Director of the Board Melbourne, Australia; June 8, 2023 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral as a Non-Executive Director of the Company’s Board of Directors. Concurrently with this appointment, Mr. Michael Sistenich has resigned as a Non-Executive Director, having served for over 7 years on the Board. Opthea’s Chairman, Dr. Jeremy Levin, commented “We are immensely grateful to Michael for his contribution to Opthea. Having joined the Board in 2015, Michael has been a valued contributor to Opthea’s growth as the Company tra..."
05/25/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea to Present at the Jefferies 2023 Healthcare Conference Melbourne, Australia; May 25, 2023 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York City on June 7-9 2023. Dr. Baldwin will present on Wednesday, June 7th at 2:00 – 2:25 PM EST , which can be accessed live by registering at: https://wsw.com/webcast/jeff281/opt/1720290. An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/. About Opthea Limited Opthea is a biopharmaceut..."
05/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea to Particpate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market Melbourne, Australia; May 17, 2023 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Elemer Piros, Senior Biotechnlogy Analyst at EF Hutton will host a webinar with Dr. Megan Baldwin, CEO and Managing Director and Timothy E. Morris, CFO of Opthea Limited on Thursday, May 18 at 5:00 pm EDT . Participates should register in advance at: https://us06web.zoom.us/webinar/register/WN_KwBdRMO9RIunOQcQJGiyLw#/registration. An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/. About Opthea Limited Opthea is ..."
05/08/2023 6-K Quarterly results
04/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ Melbourne, Australia; April 28, 2023 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that management will participate in the one-on-one meeting portion of the H.C. Wainwright BioConnect Conference being held on May 2, 2023. The Conference is produced in partnership with NASDAQ and will take place at the exchange’s world headquarters in New York City . About Opthea Limited Opthea is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration and diabetic macular e..."
03/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea Receives A$8.7 million R&D Tax Incentive Melbourne, Australia; 7 March 2023 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.7 million research and development tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2021/2022 financial year, and represents the amount disclosed in the company’s audited financial statements at 30 June 2022. The R&D tax incentive credit relates to both Australian and eligible overseas expenditure for the development of Opthea’s lead candidate OPT-302. The R&D Tax Incentive is as an Australian Federal Government program under which companies can re..."
03/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference Melbourne, Australia; March 6, 2023 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will participate in a fireside chat at Oppenheimer’s 33rdAnnual Healthcare Conference being held virtually on March 13-15, 2023. Dr. Baldwin’s conversation with Hartaj Singh, Managing Director and Senior Analyst, Biotech Equity Research at Oppenheimer, will take place on Monday, March 13th at 2:40 pm ET , and can be accessed live by registering at https://wsw.com/webcast/oppenheimer27/opt/2585247. An archive of the presentation will be availab..."
02/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASX, Nasdaq and Media Release February 23, 2023 Opthea Limited / 2023 HALF-YEAR REPORT logo February 23, 2023 Half-Year Financial Report December31, 2022 In accordancewith Listing Rule 4.2A, we enclose the Half-Year FinancialReport on the consolidated results of Opthea Limited for the half year ended December 31, 2022. The previous corresponding periods are the fiscal year ended June 30, 2022 and the half year ended December 31, 2021. Information in relation to the operational performance, financial performance, cash flows and financial positionis included in the attached Appendix 4D Half-Year Financial Report. This Half-Year FinancialReport should be read in conjunction with the Company’sAnnual Report for the year ended June 30, 2022. Karen Adams Company Secretary February 23, 2023 i Appe..."
02/13/2023 6-K Quarterly results
02/06/2023 6-K Quarterly results
01/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASX, Nasdaq and Media Release Opthea To Present at Sequire Biotechnology Conference Melbourne, Australia; 30 January, 2023 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023. Dr. Baldwin will present on Thursday, February 2nd at 10:00 am ET . To access the presentation please register at https://biotech.sequireevents.com. About Opthea Limited Opthea is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-relat..."
01/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"OPT-302 2020: IPO NASDAQ 2020 IP"
12/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
12/06/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASX, Nasdaq and Media Release Opthea to Present at the FLORetina 2022 Congress Melbourne, Australia; 6 December, 2022 – Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce a podium talk will be presented at the annual FLORetina congress, taking place in Rome, Italy from December 8-11, 2022. Dr. Caroline Baumal, MD from the Tufts University School of Medicine, New England Eye Center, Boston, Massachusetts will present on OPT-302 combination therapy in wet AMD. The talk will include the design of the ongoing Phase 3 program which will assess the primary endpoint of superiority in mean Best Corrected Visual Acuity at 12 months versus ranibizumab or aflibercept anti-VEGF-A monotherapy. The d..."
11/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea Chairman's Address to the 2022 Annual General Meeting",
"Results of 2022 Annual General Meeting"
10/24/2022 6-K Quarterly results
09/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Results of 2022 Annual General Meeting",
"Results of 2022 Annual General Meeting"
08/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights",
"Opthea Appendix 4E and Annual Report",
"Opthea Appendix 4G Corporate Governance Statement 2022"
08/26/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Notice of Extraordinary General Meeting and Explanatory Notes"
08/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Share Purchase Plan - Letter to Eligible Shareholders and SPP Booklet Melbourne, Australia; 25 August 2022 - Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, confirms its share purchase plan offer opens today. Attached is: • a copy of a letter being sent to each Opthea shareholder who, as at 7.00pm on Friday, 12 August 2022, was shown on Opthea's register of shareholders to have an address in Australia or New Zealand ; and • a copy of the share purchase plan offer booklet available for download at https://opt2022spp.thereachagency.com . Eligible Shareholders who have provided an e-mail address will be sent an e-mail communication. Eligible Shareholders who have not provided an e-mail address ..."
08/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD",
"Opthea Successfully Closes Well Supported US$90 Million Equity Financing"
05/11/2022 6-K Quarterly results
05/10/2022 6-K Quarterly results
05/05/2022 6-K Quarterly results
04/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting"
04/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Initial Director’s Interest Notice – Susan Orr"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy